Immunocore Holdings plc(IMCR)— Stock Profile, AI Score & Financials

Healthcare · Nasdaq · AI-powered stock analysis, 32-signal quality score, SEC EDGAR financials, and institutional holdings. Updated 2026-06-30.

Immunocore Holdings plc (IMCR) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores IMCR at 36.6/100 on a 32-signal composite quality model, placing it at rank #2,263 of 2,961 stocks — the bottom half of the AI-ranked universe. Based on the latest XBRL financial filings (Q2 2026), Immunocore Holdings plc reports quarterly revenue of $115.9M, net income of $-808.0K, free cash flow of $15.1M. Top institutional holders of IMCR by reported 13-F value include WELLINGTON MANAGEMENT GROUP LLP, RTW INVESTMENTS, FMR, based on the most recent SEC filings. IMCR trades on the Nasdaq exchange and files with the SEC under CIK 1671927. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate IMCR daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Immunocore Holdings plc directly from SEC EDGAR.